• KOLs Community
    • Racemic
    • Racemic Albuterol
    • Warren W Pleskow
    • Warren W Pleskow

      Warren W Pleskow

      private practice, Encinitas, Calif | Radiant Research, Encinitas, California. | Radiant Research, Encinitas, California, USA. | Radiant Research, Encinitas, CaliforniaUSA | ...



      KOL Resume for Warren W Pleskow


      private practice, Encinitas, Calif


      Radiant Research, Encinitas, California.


      Radiant Research, Encinitas, California, USA.


      Radiant Research, Encinitas, CaliforniaUSA


      Allergy and Asthma Centers of Charleston, Encinitas, California.


      Denver, Colo, Stockton and Encinitas, Calif, Wilmington, NC, and Marlborough, Mass

      Scripps Memorial Hospital, Encinitas, California.


      Private Practice, Encinitas, California, U.S.A.


      Salt Lake City, Utah, Shreveport, La., Austin, Texas, Chester, Pa., Winston-Salem, N.C., Philadelphia, Pa., Fridley, Minn., San Jose, Calif., San Diego, Calif., Minneapolis, Minn., Houston, Texas, Bryan, Texas, Encinitas, Calif., San Antonio, Texas, and Kenilworth, N.J


      North Dartmouth, Mass., U.S.A.


      private practice, Encinitas, CA, USA


      Department of Allergy and Clinical Immunology, Kaiser Permanente Medical Center, San Diego, Calif., USA


      Department of Allergy and Clinical Immunology, Kaiser Petmanente Medical Center, San Diego, Calif., USA


      From the Department of Allergy and Clinical Immunology, Kaiser Permanente Medical Center-San Diego, San Diego, Calif. USA



      Warren W Pleskow: Influence Statistics

      Sample of concepts for which Warren W Pleskow is among the top experts in the world.
      Concept World rank
      hfa cumulative #1
      individual components treatment #1
      individual components patients #1
      hfa mdi hfa #1
      placebo triamcinolone acetonide #1
      pseudoephedrine individual #1
      5 240mg tablets #1
      components desloratadine #1
      levalbuterol hfa #1
      dose racemic albuterol #1
      tss excluding #1
      congestion morning #1
      mdi asthmatic #1
      excluding congestion #1
      racemic albuterol hfa #1
      patients triamcinolone acetonide #1
      pseudoephedrine morning #1
      cumulative dose study #1
      excluding nasal #1
      240 monotherapy treatment #1
      desloratadinepseudoephedrine nasal congestion #1
      desloratadinepseudoephedrine #1
      subjects levalbuterol #1
      7 21day baseline #1
      mdi racemic #1
      levalbuterol hfa mdi #1
      hfa levalbuterol #1
      95 16x dose #1
      16 cumulative doses #1
      sar moderate #1
      pef triamcinolone #1
      clinic spirometry measures #1
      hfa mdi improvements #1


      Prominent publications by Warren W Pleskow

      KOL-Index: 13659

      BACKGROUND: Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma.

      OBJECTIVE: This study evaluated the safety and efficacy of fluticasone propionate administered via the Diskus and Diskhaler powder delivery devices in subjects with mild-to-moderate asthma.

      METHODS: Fluticasone propionate (500 microg twice daily) or placebo was administered via the Diskus and Diskhaler to 213 adolescent and adult asthma subjects in a ...

      Known for Fluticasone Propionate | Treatment Asthma | Inhaled Corticosteroids | Efficacy Safety | 500 Microg
      KOL-Index: 12695

      BACKGROUND: The treatment of symptoms of seasonal allergic rhinitis often requires the use of a decongestant to improve nasal congestion, along with an antihistamine to adequately control other nasal, as well as nonnasal symptoms.

      METHODS: In this double-blind, placebo-controlled, multicenter study, 874 patients with moderate to severe symptoms of seasonal allergic rhinitis were treated with one of the following: SCH 434 QD (a combination of 10 mg of loratadine in the coating and 240 mg ...

      Known for Seasonal Allergic Rhinitis | Loratadine Pseudoephedrine | Treatment Symptoms | Nasal Congestion | Ephedrine Female
      KOL-Index: 12257

      BACKGROUND: Recent emphasis on the control of airway inflammation in asthma highlights the need for safe and effective antiinflammatory agents. Fluticasone propionate is one of the most potent antiinflammatory corticosteroids developed to date.

      OBJECTIVE: This study assessed the safety and efficacy of fluticasone propionate aerosol in the treatment of mild to moderate asthma.

      METHODS: Fluticasone propionate aerosol (25, 100, or 500 micrograms twice daily) or placebo was given for as long ...

      Known for Fluticasone Propionate | Moderate Asthma | 500 Micrograms | Airway Inflammation | Placebo Treated
      KOL-Index: 11357

      BACKGROUND: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental.

      OBJECTIVE: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in patients with moderate-to-severe asthma.

      METHODS: This was a randomized, double-blind, ...

      Known for Racemic Albuterol | Placebo Patients | 4 Weeks | Asthma Bronchodilator | Primary Endpoint
      KOL-Index: 11219

      The objectives of this study were to compare the efficacy and tolerability of twice-daily formoterol dry powder 12 microg and 24 microg (Foradil) delivered via Aerolizer inhaler with four times daily albuterol (salbutamol) 180 microg delivered via metered dose inhaler (MDI) and placebo. A total of 554 adolescents and adults (ages 12-75 years) with mild-to-moderate asthma were randomized to this 12-week, multicenter, double-blind, double-dummy, placebo-controlled, parallel-group study. ...

      Known for Formoterol Albuterol | 12 Microg | Dry Powder | Aerolizer Inhaler | Forced Expiratory
      KOL-Index: 9380

      BACKGROUND: Antihistamine-decongestant combination products generally provide more benefit than individual components for adequately treating patients who have seasonal allergic rhinitis (SAR) with moderate-to-severe nasal congestion.

      OBJECTIVE: To compare the effectiveness and safety of a 24-hour, extended-release formulation of desloratadine and pseudoephedrine with the individual components in patients who have SAR with moderate-to-severe nasal congestion.

      METHODS: Patients with SAR ...

      Known for Nasal Congestion | Allergic Rhinitis | Desloratadine Pseudoephedrine | Patients Sar | Seasonal Treatment
      KOL-Index: 7178

      Thirty aspirin-sensitive asthmatic patients underwent incremental, oral aspirin challenge until a "positive reaction" (delta FEV1 greater than or equal to 25%) occurred. After this reaction, aspirin was readministered in an attempt to achieve "desensitization." This was defined as the ability of the patient to ingest 650 mg of aspirin without experiencing upper or lower respiratory-tract symptoms or a decrease in lung function. To determine the "refractory period" following aspirin ...

      Known for Aspirin Desensitization | Asthmatic Patients | Positive Reaction | Clinical Manifestations | Sensitivity Cross
      KOL-Index: 4938

      Twenty-five ASA-sensitive patients with rhinosinusitis asthma underwent oral ASA challenges followed by desensitization to the adverse respiratory effects of ASA. We then compared the efficacy of continuous ASA treatment for their respiratory tract disease to that of a placebo treatment during a double-blind crossover study. For this group of 25 patients, there was significant improvement in nasal symptoms and a reduction in use of nasal beclomethasone during the months when they ...

      Known for Rhinosinusitis Asthma | Desensitization Treatment | Nasal Symptoms | Oral Challenges | Adverse Respiratory Effects
      KOL-Index: 4606

      Nineteen aspirin sensitive adult patients were identified who experienced naso-ocular responses without associated bronchospasm during standardized oral aspirin challenge. These 19 patients exhibited the characteristics of the aspirin triad except asthma. These included hypertrophic rhinitis with or without associated nasal polyps, abnormal sinus roentgenograms, nasal eosinophilia, aspirin-provoked responses of the upper airway identical to those observed in aspirin-sensitive asthmatics, ...

      Known for Aspirin Sensitive | Upper Airway | Nasal Polyps | Clinical Syndrome | 19 Patients
      KOL-Index: 4103

      In order to determine the types of respiratory responses observed during aspirin-induced reactions, 50 consecutive asthmatic patients with a history of aspirin sensitivity underwent prospective oral aspirin challenges between 1979 and 1981. Oral aspirin challenges produced 36 asthmatic responses (33 combined with rhinitis and three purely asthmatic) and six acute rhinoconjunctivitis responses (three combined with mild asthma and three purely rhinoconjunctivitis) but failed to stimulate ...

      Known for Patients Aspirin | Respiratory Responses | Sensitive Rhinosinusitis | Drug Hypersensitivity | Forced Expiratory
      KOL-Index: 3919

      BACKGROUND: National and international guidelines recommend inhaled anti-inflammatory medications for patients with all but the mildest forms of asthma. Patients may also be more compliant with twice daily dosing.

      OBJECTIVE: To evaluate the efficacy and safety of triamcinolone acetonide (triamcinolone acetonide), 400 microg bid, in mild-to-moderate asthma patients.

      METHODS: A multicenter, randomized, double-blind, placebo-controlled study with a 7- to 21-day baseline and 6-week treatment ...

      Known for Triamcinolone Acetonide | Adult Anti | Expiratory Volume | Administration Inhalation | Agents Asthma
      KOL-Index: 2230

      BACKGROUND: The short-acting beta(2)-agonists levalbuterol and racemic albuterol are available for administration through a hydrofluoroalkane-134a (HFA) metered-dose inhaler (MDI).

      OBJECTIVE: This study compared the short-term safety and efficacy of cumulative doses of levalbuterol HFA MDI and racemic albuterol HFA MDI in asthmatic subjects.

      METHODS: This was a randomized, modified-blind, active-controlled, multicenter, 2-way crossover study. Subjects (n = 49) were randomized to 16 ...

      Known for Racemic Albuterol | Beta Agonists | Bronchodilator Agents | Short Acting
      KOL-Index: 2050
      Known for Chronic Urticaria | Antagonists Humans | Histamine H1 | Cyproheptadine Double | Loratadine 10
      KOL-Index: 1571

      Activation of complement was sought by two independent assay methods, total hemolytic complement (CH50) and C4 activation by rocket immunoelectrophoresis for C4d and C4 in plasma samples obtained from 16 aspirin-sensitive asthmatic patients and four control subjects during provocative oral aspirin challenges. No consistent evidence of significant complement activation was detected in either the asthmatic or control groups when serial measurements were performed. The measurements of CH50 ...

      Known for Complement Activation | Aspirin Challenge | Asthmatic Patients

      Key People For Racemic Albuterol

      Top KOLs in the world
      Sidney S DeGraw
      racemic albuterol pediatric patients placebo treatment
      George W Bensch
      pulmicort turbuhaler mometasone furoate racemic albuterol
      David S Reasner
      racemic albuterol pediatric patients placebo treatment
      Harold S Nelson
      allergic rhinitis sublingual immunotherapy inhaled corticosteroids
      Warren W Pleskow
      racemic albuterol fluticasone propionate seasonal allergic rhinitis
      Thomas E Rollins
      racemic albuterol improved bronchodilation patients asthma

      Warren W Pleskow:Expert Impact

      Concepts for whichWarren W Pleskowhas direct influence:Racemic albuterol,  Fluticasone propionate,  Seasonal allergic rhinitis,  Moderate asthma,  Levalbuterol racemic albuterol,  Beclomethasone dipropionate,  Asthmatic subjects,  Triamcinolone acetonide.

      Warren W Pleskow:KOL impact

      Concepts related to the work of other authors for whichfor which Warren W Pleskow has influence:Fluticasone propionate,  Aspirin desensitization,  Allergic rhinitis,  Racemic albuterol,  Persistent asthma,  Inhaled corticosteroids,  Nasal polyps.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      private practice, Encinitas, Calif | Radiant Research, Encinitas, California. | Radiant Research, Encinitas, California, USA. | Radiant Research, Encinitas, CaliforniaUSA | Allergy and Asthma Centers of Charleston, Encinitas, California.

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.